Beta-Blockers for Migraine Prevention: a Review Article

Danesh, Arash; Gottschalk, Paola

doi:10.1007/s11940-019-0556-3

Cited by 37 publications

(18 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the findings of a study from Taiwan (8), betablockers were the first choice from the series of prophylactic drugs. This might be for their strong evidence, their effectiveness and their favorable side effect profile (22,24,25). The relatively frequent use of sartans in our study is interesting, because the new guideline of spring 2018 (26) only recommends sartans as a prophylactic if there is an arterial hypertension at the same time; however, at the time of our data collection, sartans were not the first choice for prophylactic treatment.…”

Section: Discussionmentioning

confidence: 99%

Do doctors treat themselves differently than their patients? Study on the self-treatment of migraine among German neurologists and pain specialists

et al. 2020

View full text Add to dashboard Cite

Aim To investigate whether the self-treatment of migraine among neurologists and pain specialists corresponds to national medical guidelines and treatment of patients. Methods An email cross-sectional survey was sent to members of the German Society for Neurology, German Pain Society and German Migraine and Headache Society containing questions on demographics, professional experience and specialization and – in case participants suffered from migraine – questions about their migraine and its treatment. Results 175/418 (41.9%) participants suffered from migraine (m: 29.3%; f: 55.2%, 45.9 ± 10.7 years). For acute migraine attacks, 96.6 % of them use a first-line treatment according to the medical guidelines. Seventeen (9.7%) are currently taking a migraine prophylaxis, 52.9% of these use a recommended first-line prophylaxis. In all, 21.7% are not taking a prophylactic treatment despite an indication (based on number of monthly migraine days) for it, due to fear of side-effects, low intensity of migraine attacks and a sufficient effect of acute medication. This group of participants was younger, less experienced and specialized and was mainly employed (vs. self-employed) compared to those taking a prophylaxis. A total of 96.6% reported treating their patients in line with current guidelines; 14.3% would treat themselves differently when they were their own patients. Conclusion The self-treatment of acute migraine attacks for the most part complies with the guidelines but, regarding the indication for a prophylaxis, a more divergent treatment approach was observed among younger, less experienced physicians. For the majority of physicians there is no difference between self-treatment and treatment of migraine patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Do doctors treat themselves differently than their patients? Study on the self-treatment of migraine among German neurologists and pain specialists

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A more cost effective and longer standing approach to migraine prophylaxis lies in the application of the beta blocker drug class. Being the first in their class in terms of application towards migraine treatment, they are still extensively utilized as a prophylactic treatment with the benefit of a much lower cost and tolerable side effect profile [17]. Second line drugs for acute migraine treatment include those of the anti-emetic class, such as promethazine and chlorpromazine.…”

Section: Clinical Aspectsmentioning

confidence: 99%

https://researchopenworld.com/migraine-a-review-of-basic-clinical-and-translational-approaches-to-new-treatment/#

2019

ARCH Women Health Care

View full text Add to dashboard Cite

Migraine is a debilitating neurological primary headache disorder characterized by recurring unipolar headaches lasting 4-72 hours with accompaniment of nausea and sensory sensitivities. Migraine is the most common headache disorder resulting in seeking of medical care [1, 2], in addition to being one of the most debilitating chronic disease conditions in terms of both morbidity and lost economic productivity. Migraine incidence has been observed since ancient times to disproportionately affect women, and most current epidemiological assessments put current incidence estimates at 12% overall for US populations, with an incidence of 18% in women and 6% in men when stratified by sex. This dimorphism of incidence is crucial when assessing overall health of a community, specifically when concerning women's health and therefore must be taken into consideration when developing both clinical and basic models of migraine to enact the best possible outcomes of combined translational research efforts. While major recent advances have been made in the field of pharmacologic intervention for migraine with the recent approval of the anti CGRP and anti CGRP receptor antibody medications, prohibitive cost and limited access have made older treatments, such as the triptans and NSAIDs, still the most commonly utilized medications to combat migraine attacks. Current preclinical research models are heavily interested in modulation of the neuropeptide CGRP, and the phenomenon of cortical spreading depression (CSD), believed to be the underlying trigger of migraine with aura, via pharmacological intervention. Modulations of these phenomena has found to be correlated with menstrual events in women, tying back to the overarching theme of higher morbidity in women. With the advent of pharmacogenomics and personalized medicine, a new epoch of potential customizable treatments looms on the horizon, endearing those afflicted with this severely debilitating condition a new glimmer of hope as research progresses into its next phase.

show abstract

“…For instance, beta‐blockers are commonly prescribed for anxiety and migraine prophylaxis and diuretics are commonly prescribed for kidney failure and heart failure. 2 , 3 , 4 , 5 Therefore, normotensive patients may have been defined as hypertensive in the study, so the apparent magnitude of the effects of hypertension on long‐term cardio‐cerebrovascular mortality may be diminished. Likewise, normotensive patients taking the hypertensive medications for non‐hypertension‐related reasons may experience reduced cardio‐cerebrovascular mortality due to the preventive or protective effects of their medications rather than due to the treatment of any underlying cardio‐cerebrovascular pathology, thus overestimating the beneficial effects of medication adherence by combining the protective effects in normotensive patients with the therapeutic effects in hypertensive patients.…”

mentioning

confidence: 99%

Generalizability and effect size of the impact of anti‐hypertensive medication adherence on long‐term cardio‐cerebrovascular mortality

Shihora

Bono

Modak

2022

J of Clinical Hypertension

View full text Add to dashboard Cite

To the Editor,The authors read with pleasure the review paper by Kim and coworkers, titled "Clinical impact of medication adherence on 10-year cardiocerebrovascular mortality in newly diagnosed hypertensive patients," that sought to assess the impact of medication adherence on cardiocerebrovascular mortality in patients with newly diagnosed hypertension. The authors concluded that medication adherence significantly improves the 10-year mortality of newly diagnosed hypertensive patients. 1 In particular, a higher medication adherence rate was associated with better outcomes in patients suffering from hypertensionrelated complications. 1 However, the following limitations should be considered when interpreting the results of this study:The researchers identified patients with hypertension based on the ICD-10 code documented in patient medical records. For patients without a medical record, the authors used the date of starting new antihypertensive drugs as an indicator of a diagnosis of hypertension. However, many antihypertensive agents, including diuretics, betablockers, and calcium channel blockers, can be used for conditions other than hypertension. For instance, beta-blockers are commonly prescribed for anxiety and migraine prophylaxis and diuretics are commonly prescribed for kidney failure and heart failure. [2][3][4][5] There-

show abstract

Beta-Blockers for Migraine Prevention: a Review Article

Cited by 37 publications

References 74 publications

Do doctors treat themselves differently than their patients? Study on the self-treatment of migraine among German neurologists and pain specialists

Do doctors treat themselves differently than their patients? Study on the self-treatment of migraine among German neurologists and pain specialists

https://researchopenworld.com/migraine-a-review-of-basic-clinical-and-translational-approaches-to-new-treatment/#

Generalizability and effect size of the impact of anti‐hypertensive medication adherence on long‐term cardio‐cerebrovascular mortality

Contact Info

Product

Resources

About